Pharmacology & therapeutics
SGLT2 inhibitors: Do they have antiarrhythmic properties?
Ricardo Caballero, Juan Tamargo, Eva Delpón
Published: 202610.1016/j.pharmthera.2025.108973
Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent the cornerstone of therapy in patients with type 2 diabetes (T2D), heart failure (HF), or chronic kidney disease (CKD). These patients present a high risk of cardiac arrhythmias, particular…
Preview only. Read the full abstract at the source